Brief: Crescita Therapeutics announces agreement with Taro Pharmaceuticals for Pliaglis

Crescita Therapeutics

25/04/2017 12:30

April 25 (Reuters) - Crescita Therapeutics Inc  CTX.TO  
    * Crescita Therapeutics announces agreement with Taro 
Pharmaceuticals for Pliaglis 
    * Crescita Therapeutics - entered development and 
commercialization license agreement with Taro Pharmaceuticals, 
unit of Taro Pharmaceutical Industries 
    * Crescita Therapeutics - under terms of agreement, Crescita 
has granted Taro exclusive license to rights to sell and 
distribute Pliaglis in U.S. market 
    * Crescita Therapeutics Inc - in consideration of rights 
granted under agreement taro will make an upfront, non-dilutive 
payment of US$2.0 million to Crescita 
    * Crescita Therapeutics Inc - under deal Taro will also make 
up to US$5.75 million in non-dilutive development and sales 
milestone payments to Crescita 
    * Crescita Therapeutics Inc - in addition, Crescita and Taro 
have entered into a fee-for-service development agreement 
    * Crescita Therapeutics Inc - Crescita retains all rights to 
Pliaglis in Canada and Mexico 
    * Crescita Therapeutics Inc - fee-for-service development 
with  Taro wherein co to provide services related to development 
of Pliaglis and enhanced formulation 
    * Crescita Therapeutics Inc - co to receive fees related to 
fee-for service development based on services performed 
 
Source text for Eikon:  ID:nPn6k6W21a  
Further company coverage:  CTX.TO  
 
 ((Bangalore.newsroom@thomsonreuters.com;))